Lung cancer is a heterogeneous disease at both clinical and molecular levels, posing conceptual and practical bottlenecks in defining key pathways affecting its initiation and progression. Molecules with a central role in lung carcinogenesis are likely to be targeted by multiple deregulated pathways and may have prognostic, predictive, and/or therapeutic value. Here, we report that Tumor Progression Locus 2 (TPL2), a kinase implicated in the regulation of innate and adaptive immune responses, fulfils a role as a suppressor of lung carcinogenesis and is subject to diverse genetic and epigenetic aberrations in lung cancer patients. We show that allelic imbalance at the TPL2 locus, up-regulation of microRNA-370, which targets TPL2 transcripts, and activated RAS (rat sarcoma) signaling may result in down-regulation of TPL2 expression. Low TPL2 levels correlate with reduced lung cancer patient survival and accelerated onset and multiplicity of urethane-induced lung tumors in mice. Mechanistically, TPL2 was found to antagonize oncogene-induced cell transformation and survival through a pathway involving p53 downstream of cJun N-terminal kinase (JNK) and be required for optimal p53 response to genotoxic stress. These results identify multiple oncogenic pathways leading to TPL2 deregulation and highlight its major tumor-suppressing function in the lung.
T umor Progression Locus 2 (TPL2), also known as Cancer Osaka Thyroid (COT) and MAP3K8, is a serine-threonine kinase with essential functions in innate immune cells, where it transmits signals through Toll-like receptors (1) (2) (3) , the TNF family of receptors (4) , and G protein-coupled receptors (5) . As a result, TPL2 ablation in mice ameliorates the severity of a variety of inflammatory pathologies (1, 6) , suggesting that it could be explored as a therapeutic target. In contrast, however, TPL2-deficient mice show increased susceptibility to infection with the T helper 1 (Th1)-inducing parasite T. gondii (7) and ovalbumin-induced bronchoalveolar inflammation (8) because of a T-cell intrinsic defect rather than an altered innate immune response, highlighting cell type-and stimulus-dependent roles for TPL2 in the immune system.
Early studies identified the TPL2 gene as a target of provirus insertion in Moloney Murine Leukemia Virus-induced T-cell lymphomas and Mouse Mammary Tumor Virus-induced mammary adenocarcinomas, yielding a truncated, C terminus-deleted product with transforming capacity (9, 10) . Because the overexpression of WT TPL2 did not exert similar oncogenic effects in vivo, it has been proposed that TPL2 is a proto-oncogene activated by Cterminal truncation (10) . Nevertheless, activating mutations in TPL2 have not been described in humans (11) . Although elevated levels of TPL2 have been reported in certain tumor types, a detailed comparative evaluation of TPL2 expression in human malignancy and normal tissue is missing, and its physiological role in carcinogenesis remains enigmatic. Interestingly, the overexpression of TPL2 in melanoma cells carrying oncogenic B-RAF (Rapidly Accelerated Fibrosarcoma) has recently been associated with resistance to the RAF kinase inhibitor PLX4720 because of TPL2-mediated ERK pathway reactivation (12) . In contrast, a genome-wide RNAi screen has shown that TPL2 is required for TRAIL (TNF-related apoptosis-inducing ligand)-induced apoptosis in human breast cancer cells (13) . Additionally, mice lacking TPL2 rapidly develop T-cell lymphomas under conditions of chronic T-cell stimulation (14) . Therefore, TPL2 may impact oncogenic events, including the cellular response to therapy in a tissue type-and stimulus-dependent manner.
Lung cancer is a leading cause of cancer-related deaths, reflecting the need for a better understanding of the mechanisms that underlie the development of pulmonary carcinomas (15) . In this paper, we show that TPL2 fulfills a role as negative regulator of lung carcinogenesis and describe genetic and epigenetic aberrations that lead to loss of TPL2 in a human malignancy. An important functional interaction between TPL2, cJun N-terminal kinase (JNK), and p53 affecting apoptosis is revealed, providing a telling example of how tumor cells exploit alternative pathways that lower intrinsic barriers to malignant transformation and tumor growth.
Results

TPL2 Levels Are Reduced in Human Lung Tumors and Associate with
Poor Patient Survival. The expression of TPL2 in human lung cancer and its relevance to this type of malignancy remain unexplored. We determined TPL2 mRNA levels by quantitative PCR (qPCR) in 100 nonsmall cell lung carcinomas (NSCLCs) and adjacent nontumoral tissue (Table S1 ) and observed downregulation of TPL2 expression in the tumor (Fig. 1A) . When this analysis was repeated separately for the two major lung cancer histologies, squamous cell carcinoma (SqCCL; n = 63) and adenocarcinoma (AdenoCa; n = 37), we found that the downregulation of TPL2 did not significantly differ between these groups (Fig. S1A) (χ 2 test, P = 0.556). Investigating the clinical relevance of TPL2 mRNA levels in human lung carcinomas, we found no association with TNM (Tumor, lymph Nodes, Metastasis) or differentiation status, age, sex, and smoking history (Table S1 ). However, low TPL2 expression correlated with reduced patient survival both in the overall NSCLC cohort (log rank test; P = 0.009) (Fig. 1B) and after adjustment for histology (Fig. S1B ). In line with this prediction was the inverse correlation between TPL2 mRNA levels and Ki67 proliferation index (Fig. 1C) , indicating that reduced levels of TPL2 expression are associated with a more aggressive tumor phenotype.
Lower expression of TPL2 was confirmed in protein lysates from representative primary lung tumor specimens vs. nonmalignant tissue from the same patients (Fig. 1D ). To verify that this reduction reflects changes in the tumor cells, we analyzed TPL2 by immunohistochemistry in 20 representative NSCLC specimens containing malignant and nonmalignant epithelium in the same section. The results showed that nontumoral lung epithelial cells display maximal immunostaining compared with adjacent malignant cells (Fig. 1E) , thus confirming our RT-qPCR data. Collectively, these observations suggest that the down-regulation of TPL2 may represent a broader phenomenon in NSCLC, which impacts on patient survival and merits additional investigation and validation in larger clinical studies.
TPL2 Deficiency Enhances Susceptibility to Experimental Lung Carcinogenesis. The aforementioned findings prompted us to experimentally evaluate the functional significance of TPL2 down-regulation in lung cancer. Chemical carcinogens have been extensively used to model multistage human lung carcinogenesis in the mouse (reviewed in refs. 16 and 17) . Among them, urethane is a commonly used carcinogen, which reproducibly causes lung tumors in mice with histological and molecular features similar to human lung AdenoCa (18) (19) (20) (21) . These aberrations include mutational activation of K-ras (Kirsten rat sarcoma viral oncogene homolog) in a proportion of carcinogen-induced tumors and inactivation of tumor suppressor genes such as p53, reminiscent of the partial (approximately 20%) incidence of K-ras mutations and frequent (>75%) loss of p53 function in human lung cancer (17) . Currently, there are no mouse models for SqCCL (16, 17) , precluding experimental analysis of the role of TPL2 in this lung tumor type.
We, thus, examined the relative susceptibility of TPL2 −/− vs. TPL2 +/+ mice to develop lung AdenoCas after exposure to urethane. At 4 mo posttreatment, all TPL2 −/− mice were found to already harbor multiple lung adenomas, whereas only hyperplasia, without atypia, had developed in WT animals ( Fig. 2 A and B) . Ki67 staining was increased in hyperplastic lesions from TPL2 −/− compared with TPL2 +/+ mice ( Fig. 2 E and F) . At 6 mo after urethane administration, lungs from TPL2 −/− animals (or heterozygous TPL2 +/− mice) contained significantly higher numbers of AdenoCas compared with TPL2 +/+ mice ( Fig. 2 A, B , and D).
The tumors developed in TPL2
−/− mice showed loss of normal alveolar architecture, increased nuclear/cytoplasmic ratio, cytologic atypia, and invasion into adjacent bronchioles. At 12 mo, the effect of TPL2 deficiency was macroscopically evident by the dramatic difference in both the number and size of lung tumors developed in these animals (Fig. 2C) , indicating that TPL2 not only influences the carcinogenic process at an early stage but could also exert negative effects during tumor growth. In line with this observation and the findings in human tissue (Fig. 1C) , lung tumor cells isolated from urethane-treated TPL2 +/+ mice express reduced levels of TPL2 compared with normal bronchial epithelium (Fig. S2A) , and the knockdown of TPL2 in H1299 human lung carcinoma cells (Fig. S2B ) increased their anchorageindependent growth in vitro (Fig. S2C) . We have recently reported that TPL2 ablation enhances inflammation induced by the Apc min mutation, resulting in dramatic increase in polyposis (22) . Theoretically, an exaggerated inflammatory response caused by urethane administration in TPL2 −/− mice could be responsible for their increased susceptibility to lung tumorigenesis. We, thus, analyzed immune cell content in lungs and spleens from TPL2 −/− and TPL2 +/+ mice at 2 and 10 wk after urethane treatment (that is, during the early stages of adenoma development). By using flow cytometric analysis of CD3 + myeloid-derived suppressor cells, natural killer, and natural killer T cells in the spleens of TPL2 −/− and TPL2 +/+ mice exposed to urethane or histological assessment of H&E-stained lung tissue sections, we did not detect statistically significant differences between strains (Fig. S3) . Additionally, urethane did not elevate the expression of soluble mediators of inflammation, such as TNF and IL-6, in blood serum (measured by ELISA) and lung tissue (measured by qPCR) above background levels during this time course. Collectively, although we cannot exclude the possibility that TPL2 may also function in the immune system to enhance chemical-induced carcinogenesis, our data do not indicate an association between TPL2 status and heightened systemic or local inflammation at early stages of urethane-induced lung carcinogenesis, thus suggesting that TPL2 functions predominantly in lung epithelial cells to negatively regulate malignant transformation.
Genetic and Epigenetically Controlled Mechanisms Account for TPL2
Down-Regulation in Human Lung Cancer. The aforementioned clinical ( Fig. 1 and Fig. S1 ) and experimental ( Fig. 2 ) data warranted additional investigations into the molecular mechanisms that account for the reduced TPL2 expression in human lung cancer.
We first examined the frequency of loss of heterozygosity (LOH) at the TPL2 locus (chromosome 10p, nucleotides 30722866-30750761). We used fluorescent microsatellite analysis at four positions on the TPL2 gene (two internal and two flanking) (Fig.  3A) to assess LOH in the available set of human primary lung tumors. As shown in a representative analysis in Fig. 3B and collective data in Fig. S4A , allelic imbalance at the TPL2 locus was observed in a significant 52% of NSCLC. The frequency of LOH at the TPL2 locus was similar between SqCCL and AdenoCa ( Fig. S4 A and B) (P = 0.954). Cases with LOH displayed lower TPL2 mRNA levels but at borderline significance (MannWhitney test, P = 0.051) (Fig. 3C ), indicating the contribution of additional mechanisms affecting TPL2 expression in lung cancer.
We surmised that TPL2 could be subject to epigenetic silencing, which was observed in certain lung tumor suppressor genes (23) (24) (25) . The presence of a putative CpG (CG dinucleotide) island located at positions −973 to +981 relative to the TPL2 transcription start site (Fig. 3A) , indicated by in silico analysis (http:// cpgislands.usc.edu/), was in line with this notion. We performed pyrosequencing methylation analysis (PMA) in our panel of 100 primary lung tumors and paired nontumoral tissue (Fig. S5) . Collectively, the results showed absence of TPL2 promoter methylation in both malignant and nonmalignant lung tissue. Previous work has shown that microRNA-370 (miR-370) negatively regulates the expression of TPL2 in malignant cholangiocytes in vitro (26) . In agreement with this report, we have found that transfection of miR-370 in A549 lung cancer cells results in a time-dependent reduction in TPL2 protein (Fig. 4A ) and mRNA levels, whereas an unrelated miR-328 had no effect. To determine if this pathway could operate in vivo, we assessed miR-370 expression by qPCR in the lung cancer set under evaluation. This analysis showed that miR-370 levels are significantly elevated in the malignant vs. nonmalignant lung tissue (Fig. 4B) and that miR-370 up-regulation was independent of histology ( Fig. S4C) .
Because miR-370 is embedded in a CpG island and subject to epigenetic control (26), we evaluated by PMA the methylation status of this region in lung cancer (Fig. 4C) . The results showed a statistically significant reduction of miR-370 methylation levels in the tumor tissue (Fig. 4D) . Moreover, this reduction closely correlated with the methylation status of the retrotransposable long interspersed nuclear element-1 (LINE-1), a surrogate marker of global methylation (27, 28) , suggesting that miR-370 hypomethylation in NSCLC is most likely the result of global genome hypomethylation (Fig. 4E) .
Oncogenic RAS Mediates Down-Regulation of TPL2. Activating mutations in ras genes have been recorded in 10-25% of lung tumors. A recent study has shown that oncogenic RAS stimulates a TANKbinding kinase 1 (TBK1)-dependent signaling pathway in vitro, which leads to reduction in p105 NF-κB1 protein levels (29) . NF-κB1 physically interacts with and regulates the stability of TPL2, which was highlighted by the fact that TPL2 is absent in macrophages (30, 31) and lung tissue (Fig. S2A ) from NFKB1 −/− mice. We, therefore, reasoned that, by modulating NF-κB1 levels, activated RAS may impact on TPL2 expression.
We have explored this association in A549 and H1299 human lung carcinoma cells stably transfected with HA-tagged H-RAS G12V expression vector or infected with K-RAS G12V -expressing retrovirus, respectively. Interestingly, the expression of either form of oncogenic RAS mediated dramatic down-regulation of TPL2 concomitant to reduction in p105 NF-κB1 expression ( Fig. 5 A and B) .
Evaluation of the mutational status of K-ras codons 12 and 13 by direct sequencing in the lung cancer set used in our study identified only 5 of 37 (13.5%) AdenoCas and 4 of 63 (6.3%) squamous carcinomas to carry K-ras mutations (Fig. S6 ). Because the incidence of LOH in the TPL2 locus (Fig. 3) supersedes the frequency of ras mutations, we could not establish a direct correlation between mutated RAS and expression of TPL2 in vivo. However, as shown in Fig. 5C , reduced levels of TPL2 were observed in lysates from mouse lungs expressing K-RAS G12D (32) , suggesting that oncogenic RAS may contribute to the downregulation of TPL2 expression in vivo.
Down-Regulation of TPL2 Levels Impacts on Cell Survival and
Oncogenic Transformation Through Regulation of p53. The operation of multiple mechanisms (LOH, miR-370, and mutated RAS) leading to down-regulation of TPL2 expression in vivo prompted us to explore pathways that may link TPL2 to oncogenic transformation. To this end, we transiently introduced a TPL2-expressing vector in A549/H-RAS G12V cell clones, which display strong suppression of endogenous TPL2 (Fig. 5A) , and observed decreased cell proliferation and elevated levels of apoptosis (Fig.  6A ). TPL2-mediated cytotoxicity required caspase activation, because it was abolished by treatment with the pan-caspase inhibitor zVAD-fmk. Moreover, the proapoptotic effect of TPL2 on RAS G12V -transfected cells correlated with increased p53 accumulation (Fig. 6B) and was alleviated by the RNAi-mediated knockdown of p53 (Fig. 6A) . These data suggest that TPL2 antagonizes oncogenic RAS in transformed cells, at least partly, by modulating p53 activity and apoptosis induction.
TPL2 also counteracted the oncogenic effects of K-RAS G12V in nontransformed cells. Immortalized 208F fibroblasts were transfected with K-RAS G12V in the presence or absence of a TPL2 expression vector, and cell transformation was quantified by anchorage-independent growth in soft agar. As shown in Fig. 6C , expression of TPL2 reduced the number of foci formed by activated K-RAS by 60%, whereas a kinase-inactive TPL2 mutant had no effect.
Genotoxic agents typically found in tobacco smoke and chemicals used to model lung cancer in the mouse, such as urethane, damage the respiratory epithelium, eventually leading to malignant transformation. To determine if the observed link between TPL2 and p53 applies to genotoxic insults in addition to oncogenic stress, TPL2 was knocked down in A549 cells, and cells were exposed to the DNA damaging agent cis-platin. The knockdown of TPL2 attenuated p53 accumulation and increased the survival of drug-treated cells (Fig. 6 D and E) . Importantly, the expression of two known p53-regulated genes, cdkn1a-encoding p21 and bax, were attenuated in lungs from TPL2 −/− mice exposed to urethane, highlighting the in vivo relevance of the TPL2-p53 link (Fig. 6F) . Next, we examined the mechanism by which TPL2 impacts on p53 levels. Nucleophosmin (NPM/B23) is a DNA damage-response gene (33) that negatively regulates the interaction of p53 with HDM2 and thus, controls p53 stability (34, 35) . Our in silico analysis of the NPM promoter (36) indicated the presence of multiple binding sites of cJun/AP1, a transcription factor that is activated by the JNK signaling pathway. Because TPL2 directly phosphorylates MKK4/7 (the JNK kinases) (37, 38), we surmised that TPL2 may influence the p53 response through JNK-mediated NPM transactivation. Indeed, TPL2 knockdown attenuated both JNK phosphorylation and NPM up-regulation in cis-platin-treated cells (Fig. 6E) . Conversely, the overexpression of TPL2 in A549/H-RAS G12V clones stimulated JNK phosphorylation and led to increased NPM levels concomitant to p53 stabilization (Fig. 6G) .
To provide additional evidence supporting the association between JNK signaling and NPM transactivation, A549 cells were exposed to the JNK inhibitor SP600125 before cis-platin treatment. As shown in Fig. 6 H and I, inhibition of JNK activity diminished the effect of cis-platin on NPM protein and mRNA expression levels. Collectively, these observations identify TPL2 as a physiological regulator of p53 that operates through a JNK-NPM signaling pathway.
Discussion
The substantial variability that typifies the genomes of malignant cells within a tumor (39) has generated conceptual and practical bottlenecks in defining key pathways affecting initiation and progression of malignancy. Molecules with a central role in carcinogenesis are likely to be targeted by multiple deregulated pathways and may have prognostic, predictive, and/or therapeutic value. We, thus, reason that the operation of multiple genetic (LOH and ras mutations) and epigenetic (miR-370) aberrations leading to loss of TPL2 in human lung cancer of both major histological types, SqCCL and AdenoCa, cannot be coincidental and points to a previously unappreciated significant role for the TPL2 pathway in this type of malignancy. This notion is corroborated by the poor prognosis of lung cancer patients carrying reduced TPL2 tumor levels and the reverse association of TPL2 expression with Ki67 index (Fig. 1 and Fig. S1 ). Additional evidence is provided by the demonstration that TPL2-deficient mice display increased susceptibility to chemically induced lung carcinogenesis (Fig. 2) . This finding, coupled with our recently published work showing that TPL2 ablation enhances the oncogenic potential of the Apc min mutation in the gut (22) , indicates that TPL2 may have a broader role as a negative regulator of carcinogenesis. However, whereas the enhancement of polyposis in Apc min/+ /TPL2 −/− mice was found to be partially (but not exclusively) hematopoietic celldriven, the in vitro and in vivo data presented in this paper suggest that TPL2 also confers powerful effects on epithelial cells in response to genotoxic and oncogenic insults. These observations are in agreement with the mechanism of action of urethane, which metabolizes to mutagenic mediators in Clara and type II alveolar epithelial cells (the progenitors of lung adenomas) (16, 17) , and the finding that the accelerated early lesions observed in TPL2 −/− mice occur in the absence of heightened systemic or local inflammatory response compared with WT animals (Fig. S3) .
Human lung cancer is characterized by extensive alterations of microRNA expression and allelic imbalance, which may influence cancer-related genes and thus, impact on patient survival (23, 40) . Known targets of LOH in lung cancer include tumor suppressor genes, such as RASSF1A, p16, and p53 (15) . Our data show that the TPL2 gene locus is subject to LOH in a human malignancy, resulting in reduced TPL2 expression (Fig. 3) .
The molecular mechanisms accounting for the altered expression of microRNAs in lung cancer are unclear (23, 40) . Our finding that miR-370 is up-regulated in primary lung tumors and closely associated with reduced TPL2 levels (Fig. 4) expands our appreciation of the in vivo effects of microRNAs on gene expression. Moreover, our data reveal a mechanism of in vivo regulation of microRNA expression influenced by global DNA hypomethylation. Aberrant methylation of CpG dinucleotides is a commonly observed epigenetic modification in human malignancies and includes both global genomic hypomethylation and hypermethylation of gene promoter regions. The latter is often associated with transcriptional silencing of tumor suppressors, such as p16, FHIT (fragile histidine triad protein), APC (Adenomatous polyposis coli), and DAPK (death-associated protein kinase), in lung cancer (15) . Despite the presence of a rich CpG island in the TPL2 promoter, we found no evidence that it is differentially methylated in tumor vs. normal lung tissue. However, we report that TPL2 gene expression may indirectly be affected by global genomic DNA hypomethylation through the epigenetic regulation of miR-370. Indeed, a close association between miR-370 and LINE-1 methylation indexes was noted in primary human lung tumors (Fig. 4E) . Hypomethylation of LINE-1 serves as a surrogate marker of global methylation status (27) , correlates with genomic instability (28) , and has been identified as an independent marker of poor prognosis in early stage NSCLC (41) . It is, thus, tempting to speculate that the down-regulation of TPL2 caused by miR-370 hypomethylation may impact on the early stages of the disease in humans, similar to the effects of TPL2 ablation on urethaneinduced lung cancer initiation in the mouse.
Clinical studies have shown that 10-25% of human AdenoCas and ∼7% of SqCCLs of the lung carry activating mutations in K-ras (23, 42) and H-ras (43, 44) genes, which represent an early event in lung carcinogenesis and mark poor prognosis. Experimental evidence supporting the role of this gene in lung cancer comes from transgenic mice expressing mutated K-ras, in which atypical adenomatous hyperplasia and AdenoCa develop (16, 17) . In these models, high expression of oncogenic RAS promotes carcinogenesis through a signaling pathway that critically depends on c-RAF (45) and NF-κB (21, 46) . In vitro analyses based on RNAi screens also point to NF-κB and the atypical IκB kinase family member TBK1 as positive regulators of survival and tumorigenicity of human lung cancer cells bearing mutated K-ras (29). In contrast, WT RAS functions as an endogenous suppressor of its mutated counterpart, and the oncogenic effects of activated K-RAS largely depend on loss of a WT ras allele (19) . Expression of WT ras and low K-ras oncogene copy number have also been proposed to account for the observation that certain lung cancer cell lines carrying mutated K-ras allele, including A549, do not display dependency (addiction) on the endogenous K-ras oncogene, inasmuch as their proliferation, survival, ERK phosphorylation, or PI3K activation status remain unaffected on RAS knockdown (47) . Data presented in this paper show that elevated levels of oncogenic RAS mediate the down-regulation of TPL2 in vitro (Fig. 5 A and B) and in vivo (Fig. 5C ) and that coexpression of these genes is incompatible for optimal tumor cell survival and malignant transformation in vitro (Fig. 6 A and C) . These findings, thus, identify TPL2 as a physiological antagonist of activated RAS in both transformed and nontransformed cells (Fig. 7) .
Which is the molecular pathway that orchestrates the tumorsuppressive effects of TPL2? Our results show that, in response to oncogenic or genotoxic stress, TPL2 participates in JNK- dependent up-regulation of NPM, thereby influencing p53 stabilization (Fig. 7) ; p53 is a major factor in preventing transformation and has a crucial role in tumor suppression, in part by regulating apoptosis, a barrier to cancer (48) . Molecular aberration leading to loss of p53 function occurs in 50-70% of AdenoCas (23) and nearly all SqCCLs (44) . We show that low TPL2 levels lead to diminished JNK and p53 responses, reduced cell death, and accelerated malignant transformation (Fig. 6 and Fig. S1 ). In line with these in vitro findings, the absence of TPL2 in mouse lungs associates with diminished p53 responses to the mutagen urethane, which were determined by the impaired up-regulation of two p53 target genes, bax and cdkn1a (Fig. 6F) . Collectively, these data define TPL2 as a regulator of the p53 pathway and provide a mechanistic explanation for the operation of multiple pathways leading to down-regulation of TPL2 in human lung cancer (Fig. 1) . However, TPL2 may have a broader role in dictating the balance between cell survival and death, thereby influencing tumorigenicity and/or the response to therapy. Indeed, an RNAi screen performed in breast cancer cells has shown that reduced TPL2 expression associates with resistance to TRAILinduced apoptosis (13), a p53-independent process (49) .
Our findings, coupled with a recent study describing a lung tumor suppressor function for the JNK kinase MKK7 (mitogenactivated protein kinase kinase 7) (32), expand our appreciation of the impact of MAP3Ks in malignancy. Similar to TPL2, inhibition of MKK7 leads to reduced JNK activation and p53 response in lung cancer cells (32) , providing a telling example of how tumor cells exploit MAPK pathways to lower intrinsic barriers to malignant transformation.
Materials and Methods
Human Tissue. Frozen tissues from 124 NSCLCs (46 AdenoCas and 78 SqCCLs) as well as 100 adjacent normal lung tissues were obtained from Liverpool Heart and Chest Hospital. In 100 NSCLCs, matched normal tissue was available; 82 patients were males, and 44 patients were females. Specimens comprised the following pathological stages: 8 T1, 103 T2, 9 T3, and 2 T4. Immunohistochemical detection of TPL2 was performed as previously described (50) .
DNA and RNA Isolation and cDNA Synthesis. DNA and total RNA extraction from tissues was performed using the DNeasy and miRNeasy Kits (Qiagen), respectively, following the manufacturer's protocol; 20 × 40-μm frozen sections from each patient sample were used. The first and last sections underwent pathological review to ensure ≥80% tumor cell content, and 500 ng total RNA were reverse-transcribed in a 20-μL reaction using the Quantitect Kit (Qiagen) following the supplier's protocol.
qPCR Expression Assays. TaqMan gene expression assays for human COT [MAP3K8; ID Hs00178297_m1, FAM (6 -Carboxyfluorescein)-labeled] and β-actin (ACTB; 4326315E) as endogenous control (VIC-labeled), mouse Cdkn1a, (Mm04205640_g1), bax (Mm00432051_m1), and GAPD (glyceraldehyde-3-phosphate dehydrogenase) assays were obtained from Applied Biosystems and used on an Applied Biosystems 7500 FAST Real-Time PCR Instrument. For microRNA analysis, the hsa-miR-370 (assay ID 2275) and RNU48 (assay ID 1006) were used as target and endogenous control, respectively, following the manufacturer's protocol. All assays were run in triplicate, and the mean value was used for the analysis. mRNA and microRNA levels were expressed as relative quantification (RQ) values, which were calculated as RQ = 2 (−ΔΔCt) , where the expression of IMR-90 human lung fibroblasts was used as a calibrator in each run. Allelic Imbalance Analysis. Primers flanking the repeat regions MS1-4 were designed (Fig. 3A) , and their sequences are provided in SI Materials and Methods. The thermal profile was 95°C for 5 min followed by 25 cycles of 94°C for 30 s, 52°C for 30 s, and 72°C for 30 s. Two microliters PCR reactions were mixed with 10 μL formamide, denatured at 95°C for 2 min, chilled on ice, and analyzed on a 3130 capillary sequencer (Applied Biosystems). Genemapper software was used to analyze the signal and quantify allelic peak areas. Allelic imbalance was scored if the allelic ratio tumor/normal was outside the region of 0.75-1.25 (52) .
DNA Methylation
Mutational Analysis of Human K-ras. K-ras mutational analysis for the hot-spot codons 12 and 13 was carried out by PCR and direct sequencing using primers described in SI Materials and Methods. Mutations were determined by comparing each tumor with the K-ras codon 12/13 WT sequence (GGTGGC).
Cell Culture, Transfections, RNAi, and Apoptosis Assays. Lung cancer cell lines (ATCC) were passaged for fewer than 6 mo after resuscitation and cultured according to the provider's instructions. Cells are authenticated by short tandem repeat profiling analysis. Liposome-mediated transfections were performed using lipofectamin (Invitrogen) in Optimem media (Invitrogen) according to the instructions of the manufacturer. RAS G12V expression vectors were a gift from A. Malliri (Paterson Institute for Cancer Research, Manchester, United Kingdom). The p53 shRNA vector was provided by Reuven Agami (The Netherlands Cancer Institute, Amsterdam, The Netherlands). TPL2 expression vectors have been previously described (2) . For the delivery of siRNAs and miR370, 5 × 10 4 A549 cells were plated into each well of a 24-well plate (Costar), and two rounds of transfection with siRNA duplexes were performed as previously described (4). The COT siRNA (AM16708) and miR-370 (hsa-miR-370) were from Ambion (Applied Biosystems). Cell survival was determined using fluorescence microscopy of propidium iodide-stained cells and MTT (Dimethyl thiazolyl diphenyl tetrazolium salt) conversion assays as previously described (4).
Soft Agar Assay. Tissue culture dishes (60 mL) were layered with 3 mL 0.7% (wt/vol) SeaPlaque Low Melting Point Agarose (FMC Bioproducts) dissolved in serum-containing medium. Cells were then mixed with 1.6 mL 0.35% (wt/vol) warm agar (42°C) in serum-containing medium and plated on the solidified agarose layer in triplicates. Fresh agar was added weekly, and cellular foci were enumerated on day 17. Antibodies and Immunoblotting. The following Abs were used for immunoblotting, which was performed as previously described (4) (53) . Briefly, 7-wk-old mice were injected i.p. with 1 mg freshly prepared urethane (Sigma-Aldrich) in 0.9% wt/vol NaCl per gram body weight one time per week for a total of 10 doses. Lungs were excised at various time points, fixed overnight in 10% buffered formalin, and paraffin-embedded. Sections cut into 4-μm size were prepared, placed on glass slides, stained with H&E, and reviewed by the study pathologists (V.P., E.N.S., and V.G.) blindly and in consensus in case of discrepancy more than 10%. The same procedure was followed for lung inflammation grade evaluation. The histopathological classification of the pulmonary lesions was performed in accordance with the recommendations of the mouse models of the human cancers consortium (National Institutes of Health/National Cancer Institute, 2004) (54). To estimate the growth rate of tumors, the percentage of tumor cells expressing the proliferation marker Ki67 was measured. A proliferation index was calculated for each tumor lesion by counting the total number of tumor cell nuclear profiles and the number of Ki67-positive nuclear profiles in randomly selected fields. Spleens from euthanized animals at 2 or 10 wk after urethane administration were processed for flow cytometry as previously described (4) . Lysates from mouse lungs expressing K-RAS G12D (32) were provided by Josef Penninger, Austrian
Academy of Sciences, Vienna, Austria.
Mouse Splenocyte Isolation and FACS Analysis. Mouse splenic cells were isolated as previously described (4) and stained with fluorescently labeled antibodies (clones are indicated in parentheses) against CD3 (145-2C11), NK1.1 (PK136), CD4 (GK1.5), CD8α (53-6.7), CD69 (H1.2F3), F4/80 (BM8), CD11c (N418), Gr1 (RB6-8C5), and CD11b (M1/70; purchased from eBioscience).
Statistical Analyses. The one-sample Smirnov-Kolmogorov test was used to assess normal distribution in continuous variables (e.g., expression and methylation levels). In the absence of normal distribution, nonparametric tests were used. The Mann-Whitney (independent) and Wilcoxon ranking (paired comparisons) tests were used to determine significant differences in expression and methylation levels among groups. Pearson χ 2 test was performed to assess differences in categorical data groups, whereas Spearman correlation assessed the relationship between continuous variables. Survival analysis was undertaken by constructing Kaplan-Meier curves and using log-rank test.
Ethics Statement. Ethical approval has been obtained from the Liverpool Ethics Committee for this study involving human tissue, and informed consent was obtained from each individual. Animal experiments were approved by the local ethics committee of the University of Crete Medical School, Greece (license number 1406/14-03-2006) in line with the corresponding national and European Union legislation.
